The Food and Drug Administration has issued a warning urging patients and doctors to verify the authenticity of their Ozempic prescriptions following the seizure of fake versions of the diabetes drug in the United States. The maker of Ozempic, Novo Nordisk, reported to the FDA on April 3 that counterfeit 1-milligram injections were being distributed outside of their authorized supply chain. The counterfeit products, labeled with specific lot and serial numbers, were seized by the FDA on April 9. While six adverse events have been reported, none are believed to be related to the fake products. Testing is currently being done to determine the safety of the counterfeit drugs.
The demand for Ozempic, used both for diabetes and weight loss, has led to an increase in counterfeit products entering the market. The FDA previously seized fake versions of Ozempic in December 2023, and warned that more may still be available for purchase. Compounded versions of the drug, which are similar but not identical to the genuine product, have also become popular. The FDA allows these compounded versions under special circumstances such as shortages. In February, a shortage of Ozempic and Wegovy was resolved, leading to the end of the sale of cheaper compounded versions. Patients and healthcare providers are advised to be vigilant and ensure they are obtaining genuine medication to avoid potential risks.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
